State Street
SGMT icon

State Street’s Sagimet Biosciences SGMT Stock Holding History

State Street’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
1,995,092
+1,866,304
+1,449% +$12.7M ﹤0.01% 2494
2026
Q1 		$673K Buy
128,788
+11,400
+10% +$63.5K ﹤0.01% 3581
2025
Q4 		$695K Buy
117,388
+6,900
+6% +$49.6K ﹤0.01% 3604
2025
Q3 		$758K Buy
110,488
+10,688
+11% +$86.7K ﹤0.01% 3574
2025
Q2 		$760K Hold
99,800
– – ﹤0.01% 3543
2025
Q1 		$325K Buy
99,800
+15,700
+19% +$65.9K ﹤0.01% 3707
2024
Q4 		$378K Buy
84,100
+29,900
+55% +$151K ﹤0.01% 3696
2024
Q3 		$150K Hold
54,200
– – ﹤0.01% 3885
2024
Q2 		$185K Sell
54,200
-229,152
-81% -$1.05M ﹤0.01% 3845
2024
Q1 		$1.54M Buy
283,352
+202,700
+251% +$1.46M ﹤0.01% 3363
2023
Q4 		$437K Buy
80,652
+50,076
+164% +$236K ﹤0.01% 3670
2023
Q3 		$269K Buy
+30,576
New +$407K ﹤0.01% 3847

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

State Street's SGMT Position: Q2 2026 in Review

State Street increased its Sagimet Biosciences (SGMT) stake by 1,449% in Q2 2026, buying an estimated $12.7M and bringing the position to 1,995,092 shares worth $15.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

State Street first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • State Street held 1,995,092 shares of Sagimet Biosciences worth $15.4M as of Q2 2026.
  • State Street bought 1,866,304 Sagimet Biosciences shares in Q2 2026, an estimated $12.7M.
  • Sagimet Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2494 holding.
  • State Street first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.